876299-47-7

Usage

Classification

Chlorinated phenol derivative

Common Uses

Disinfectant, antiseptic agent

Properties

Antimicrobial and antifungal
Effective against bacteria and fungi

Industrial Applications

Controls and prevents microbial growth
Used in various industrial processes

Medical Applications

Antiseptic for medical purposes
Incorporated into pharmaceutical products

Chemical Synthesis

Intermediate in organic compound synthesis
Used in the production of pharmaceuticals

Health Hazards

Toxic to aquatic organisms
Causes irritation and sensitization in humans

Environmental Impact

Potential hazard to aquatic ecosystems

Regulatory Considerations

Subject to regulations regarding usage and disposal

Upstream product

• 56961-30-9 2-chloro-5-hydroxybenzoic acid 

Downstream Products

• 7310-94-3 2-chloro-5-hydroxybenzaldehyde 
• 876300-70-8 {2-chloro-5-[(phenylmethyl)oxy]phenyl}methanol 
• 222623-28-1 4-chloro-3-(chloromethyl)phenol 

Relevant academic research and scientific papers

Synthesis of ent-Ketorfanol via a C-H Alkenylation/Torquoselective 6π Electrocyclization Cascade

The asymmetric synthesis of ent-ketorfanol from simple and commercially available precursors is reported. A RhI-catalyzed intramolecular C-H alkenylation/torquoselective 6π electrocyclization cascade provides a fused bicyclic 1,2-dihydropyridin

N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INHIBITORS

The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.

Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors

A compound of formula (I), or a pharmaceutically acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p38-mediated disease, disorder, or condition, in particular the allergic and non-allergic airways diseases, more particularly obstructive or inflammatory airways diseases, preferably chronic obstructive pulmonary disease.